Long-term treatment with Ofev (nintedanib) can safely slow disease progression in people with idiopathic pulmonary fibrosis (IPF), new four-year data from INPULSIS-ON, an open-label Phase 3 extension trial, show. The findings were reported in “Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from…
News
Treatment of idiopathic pulmonary fibrosis (IPF) with Esbriet (pirfenidone) leads to stable lung function over two years, according to a real-world study. The data matches previous results from Phase 3 trials. The research, “Functional decline over time in patients with IPF treated with pirfenidone: the…
A comprehensive Swedish study reveals low use and lack of persistence with Esbriet (pirfenidone) treatment among patients with pulmonary fibrosis (PF). Results of this real-world study were presented in a poster titled “Pirfenidone Use in a Swedish Cohort of Patients With Pulmonary Fibrosis” during the…
The National Institutes of Health (NIH) has granted $12 million to researchers at Cedars-Sinai Medical Center to continue studying two lung diseases — idiopathic pulmonary fibrosis and chronic lung allograft dysfunction. Idiopathic pulmonary fibrosis (IPF) is characterized by progressive scarring of lung tissue which leads to difficulty breathing. Chronic lung allograft dysfunction is a complication…
FibroGen’s investigational compound pamrevlumab has received fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF). The agency’s decision follows review of the double-blind PRAISE Phase 2b study (NCT01890265) results, which showed that, over 48 weeks, intravenous…
September is recognized as Pulmonary Fibrosis (PF) Awareness Month, and the Pulmonary Fibrosis Foundation (PFF) is suggesting a host of ways to get involved in increasing awareness for the disease. Last year, PFF’s awareness efforts on social media reached 915,000 people. This year, the organization hopes to increase that…
The American Lung Association is promoting Pulmonary Fibrosis Awareness Month through September with educational videos featuring lung transplant recipient Randy Cooke, who shares his tips and experience in dealing with idiopathic pulmonary fibrosis (IPF), the most common form of the disease. September was originally designated Pulmonary Fibrosis Awareness…
A research team from the University of Arizona (UA) College of Medicine – Tucson was given a $4.4 million grant from the U.S. Department of Defense to study two experimental treatments believed to delay or possibly reverse excessive scar tissue formation in the lungs of patients with…
Low levels of the homeobox only protein x (HOPX) in lung samples from idiopathic pulmonary fibrosis (IPF) patients are linked to lung function decline and disease progression, a new study suggests. The study, “Dynamic expression of HOPX in alveolar epithelial cells reflects injury and repair during the…
The Envisia Genomic Classifier test for idiopathic pulmonary fibrosis (IPF) diagnosis received a draft Medicare local coverage determination (LCD) through the MolDx (Molecular Diagnostics) service program, according to Veracyte. The decision is a key step in making the test widely available to patients, the company says.
